Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Active, not recruiting

Brief Summary: The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.

Recruitment & Eligibility

Inclusion Criteria

Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period
Patients who were diagnosed with BC during the index period

Exclusion Criteria

Primary Outcome Measures

Name	Time	Method
Total treatment duration and cycle for Palbociclib	From index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the end date of last palbociclib prescription (maximum of 34.8 months from the index date)

Secondary Outcome Measures

Name	Time	Method
Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting.	From the index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the time of reduction or increase in the dose given in the subsequent Palbociclib prescription (up to 30 Sep 2020)

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial